Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul;19(7):1411-8.
doi: 10.1681/ASN.2007111202. Epub 2008 Apr 2.

Sirolimus is associated with new-onset diabetes in kidney transplant recipients

Olwyn Johnston  1 , Caren L Rose, Angela C Webster, John S Gill
Affiliations

Sirolimus is associated with new-onset diabetes in kidney transplant recipients

Olwyn Johnston et al. J Am Soc Nephrol. 2008 Jul.

Abstract

New-onset diabetes (NOD) is associated with transplant failure. A few single-center studies have suggested that sirolimus is associated with NOD, but this is not well established. With the use of data from the United States Renal Data System, this study evaluated the association between sirolimus use at the time of transplantation and NOD among 20,124 adult recipients of a first kidney transplant without diabetes. Compared with patients treated with cyclosporine and either mycophenolate mofetil orazathioprine, sirolimus-treated patients were at increased risk for NOD, whether it was used in combination with cyclosporine (adjusted hazard ratio [HR] 1.61; 95% confidence interval [CI] 1.36 to 1.90),tacrolimus (adjusted HR 1.66; 95% CI 1.42 to 1.93), or an antimetabolite (mycophenolate mofetil orazathioprine; adjusted HR 1.36; 95% CI 1.09 to 1.69). Similar results were obtained in a subgroup analysis that included the 16,861 patients who did not have their immunosuppressive regimen changed throughout the first posttransplantation year. In conclusion, sirolimus is independently associated with NOD. Given the negative impact of NOD on posttransplantation outcomes, these findings should be confirmed in prospective studies or in meta-analyses of existing trials that involved sirolimus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Cumulative incidence of NOD within the first 3 yr posttransplantation by drug combination at hospital discharge from transplantation.
See this image and copyright information in PMC

Comment in

References

    1. Cosio FG, Pesavento TE, Osei K, Henry ML, Ferguson RM: Post-transplant diabetes mellitus: Increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 59: 732–737, 2001 - PubMed
    1. Kasiske BL, Snyder JJ, Gilbertson D, Matas AJ: Diabetes mellitus after kidney transplantation in the United States. Am J Transplant 3: 178–185, 2003 - PubMed
    1. Boudreaux JP, McHugh L, Canafax DM, Ascher N, Sutherland DE, Payne W, Simmons RL, Najarian JS, Fryd DS: The impact of cyclosporine and combination immunosuppression on the incidence of posttransplant diabetes in renal allograft recipients. Transplantation 44: 376–381, 1987 - PubMed
    1. Friedman EA, Shyh TP, Beyer MM, Manis T, Butt KM: Posttransplant diabetes in kidney transplant recipients. Am J Nephrol 5: 196–202, 1985 - PubMed
    1. Revanur VK, Jardine AG, Kingsmore DB, Jaques BC, Hamilton DH, Jindal RM: Influence of diabetes mellitus on patient and graft survival in recipients of kidney transplantation. Clin Transplant 15: 89–94, 2001 - PubMed

Publication types